SG11201909957TA - Engineered ligase variants - Google Patents

Engineered ligase variants

Info

Publication number
SG11201909957TA
SG11201909957TA SG11201909957TA SG11201909957TA SG 11201909957T A SG11201909957T A SG 11201909957TA SG 11201909957T A SG11201909957T A SG 11201909957TA SG 11201909957T A SG11201909957T A SG 11201909957TA
Authority
SG
Singapore
Prior art keywords
california
redwood city
penobscot
international
drive
Prior art date
Application number
Inventor
Mathew Miller
Jonathan Vroom
Nikki Dellas
Donald Baskerville
Sandy Gomes
David Elgart
Judy Viduya
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of SG11201909957TA publication Critical patent/SG11201909957TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y605/00—Ligases forming phosphoric ester bonds (6.5)
    • C12Y605/01—Ligases forming phosphoric ester bonds (6.5) forming phosphoric ester bonds (6.5.1)
    • C12Y605/01001—DNA ligase (ATP) (6.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/191—Modifications characterised by incorporating an adaptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/122—Massive parallel sequencing

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT ~ill IIIIIIIIII1101DIVIIIIIIIHo o Holommiliu imio oimIE (10) International Publication Number WO 2018/208665 Al (51) International Patent Classification: C12N 9/00 (2006.01) C12N 15/31 (2006.01) C12N 15/09 (2006.01) C12N 15/52 (2006.01) (21) International Application Number: PCT/US2018/031376 (22) International Filing Date: 07 May 2018 (07.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/503,075 08 May 2017 (08.05.2017) US 62/540,734 03 August 2017 (03.08.2017) US 62/587,030 16 November 2017 (16.11.2017) US (71) Applicant: CODEXIS, INC. [US/US]; 200 Penobscot Dri- ve, Redwood City, California 94063 (US). (72) Inventors: MILLER, Mathew„ G.; 200 Penobscot Dri- ve, Redwood City, California 94063 (US). VROOM, Jonathan; 200 Penobscot Drive, Redwood City, California 94063 (US). DELLAS, Nikki; 200 Penobscot Drive, Red- wood City, California 94063 (US). BASKERVILLE, Don- ald„ S.; 200 Penobscot Drive, Redwood City, California 94063 (US). GOMES, Sandy„ M.; 200 Penobscot Drive, Redwood City, California 94063 (US). ELGART, David; 200 Penobscot Drive, Redwood City, California 94063 (US). VIDUYA, Judy, Victoria Antonio; 200 Penobscot Drive, Redwood City, California94063 (US). (74) Agent: MACKNIGHT, Kamrin, T.; Codexis, Inc., 200 Penobscot Drive, Redwood City, California 94063 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ENGINEERED LIGASE VARIANTS FIG. 1 Temperature / Activity Profile 90 80 0 70 co 60 -A-SEQ ID NO : 38 0 50 11-WT T4 DNA ligase CU 40 4 , .04 30 7 2 20 15 20 25 30 35 40 Temperature (°C) (57) : The present invention provides engineered ligase polypeptides and compositions thereof, as well as polynucleotides C © encoding the engineered ligase polypeptides. The invention also provides methods for use of the compositions comprising the engineered N • ligase polypeptides for diagnostic and other purposes. [Continued on next page] 0 10 0 00 O 00 WO 2018/208665 Al MIDEDIMOMMIDEFIE1111111111111111111111111101111111111111111111111111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201909957T 2017-05-08 2018-05-07 Engineered ligase variants SG11201909957TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762503075P 2017-05-08 2017-05-08
US201762540734P 2017-08-03 2017-08-03
US201762587030P 2017-11-16 2017-11-16
PCT/US2018/031376 WO2018208665A1 (en) 2017-05-08 2018-05-07 Engineered ligase variants

Publications (1)

Publication Number Publication Date
SG11201909957TA true SG11201909957TA (en) 2019-11-28

Family

ID=64014642

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909957T SG11201909957TA (en) 2017-05-08 2018-05-07 Engineered ligase variants

Country Status (15)

Country Link
US (1) US20180320162A1 (en)
EP (2) EP3635101B1 (en)
JP (2) JP7401902B2 (en)
KR (1) KR20200003903A (en)
CN (1) CN110914415A (en)
AU (1) AU2018266606A1 (en)
BR (1) BR112019023337A2 (en)
CA (1) CA3062550A1 (en)
DK (1) DK3635101T3 (en)
ES (1) ES2887078T3 (en)
HU (1) HUE055411T2 (en)
MX (1) MX2019013289A (en)
PL (1) PL3635101T3 (en)
SG (1) SG11201909957TA (en)
WO (1) WO2018208665A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10837009B1 (en) 2017-12-22 2020-11-17 New England Biolabs, Inc. DNA ligase variants
CN113874521A (en) 2019-01-06 2021-12-31 10X基因组学有限公司 Method and system for enriching barcodes
EP3947722A1 (en) 2019-03-27 2022-02-09 10X Genomics, Inc. Systems and methods for processing rna from cells
CN113774032B (en) * 2021-11-12 2022-03-01 翌圣生物科技(上海)股份有限公司 Recombinant T4 ligase mutant, coding DNA and NGS library construction method
US11685913B1 (en) * 2022-02-18 2023-06-27 Abclonal Science, Inc. T4 DNA ligase variants with increased resistance to salt
US11788082B2 (en) * 2022-02-22 2023-10-17 Abclonal Science, Inc. T4 DNA ligase variants with increased thermostability
US20230295707A1 (en) * 2022-03-21 2023-09-21 Abclonal Science, Inc. T4 DNA Ligase Variants with Increased Ligation Efficiency
CN115896047B (en) * 2022-12-12 2023-06-16 南京诺唯赞生物科技股份有限公司 Recombinant T4DNA ligase mutant, fusion protein and application thereof
CN116218953A (en) * 2023-01-03 2023-06-06 南京诺唯赞生物科技股份有限公司 Method for connecting nucleic acid fragment and adaptor

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69523052T2 (en) 1994-06-03 2002-06-20 Novo Nordisk Biotech Inc PURIFIED MYCELIOPHTHORA LACCASES AND NUCLEIC ACIDS CODING THEM
CN1151762A (en) 1994-06-30 1997-06-11 诺沃诺尔迪斯克生物技术有限公司 Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein
FI104465B (en) 1995-06-14 2000-02-15 Valio Oy Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL130635A0 (en) 1997-01-17 2000-06-01 Maxygen Inc Evolution of whole cells and organisms by recursive sequence recombination
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
IL138800A0 (en) 1998-04-02 2001-10-31 Tellus Genetic Resources Inc A method of identifying a plant with a lesion in a gene sequence
KR20010082543A (en) 1998-05-01 2001-08-30 추후제출 Optimization of pest resistance genes using dna shuffling
CA2335269A1 (en) 1998-06-17 1999-12-23 Maxygen, Inc. Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
AU5347999A (en) 1998-08-12 2000-03-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
CA2345203A1 (en) 1998-10-07 2000-04-13 Maxygen Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (en) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 Semiconductor device
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
DK1072010T3 (en) 1999-01-19 2010-06-21 Maxygen Inc Oligonucleotide-mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
EP1165757A1 (en) 1999-03-05 2002-01-02 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
IL150291A0 (en) 2000-01-11 2002-12-01 Maxygen Inc Integrated systems and methods for diversity generation and screening
WO2001075767A2 (en) 2000-03-30 2001-10-11 Maxygen, Inc. In silico cross-over site selection
AU2001249811B2 (en) 2000-04-03 2006-06-08 Maxygen, Inc. Subtilisin variants
EP2278509B1 (en) 2002-03-01 2014-11-19 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
JP4851687B2 (en) 2002-03-09 2012-01-11 マキシジェン， インコーポレイテッド Crossover optimization for directed evolution
WO2005017135A1 (en) 2003-08-11 2005-02-24 Codexis, Inc. Improved ketoreductase polypeptides and related polynucleotides
HUE034642T2 (en) 2008-02-12 2018-02-28 Codexis Inc Method of selecting an optimized diverse population of variants
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
DK3023494T3 (en) 2008-06-13 2019-02-25 Codexis Inc PROCEDURE FOR SYNTHESIS OF POLYNUCLEOTIDE VARIETIES
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
KR20120093882A (en) * 2009-09-16 2012-08-23 마쎄이 유니버시티 Fusion polypeptides and uses thereof
US8697408B2 (en) 2011-05-06 2014-04-15 New England Biolabs, Inc. Ligation enhancement
EP2726651B1 (en) 2011-06-28 2018-11-07 Codexis, Inc. Protein variant generation by region shuffling
US20150010525A1 (en) * 2012-01-23 2015-01-08 The Regents Of The University Of California Catalytic Tagging System to Study Macro-Molecular Interactions Using Engineered Ubiquitin Ligase and Ubiquitin-Like Proteins to Facilitate Substrate Identification
WO2013159055A1 (en) 2012-04-20 2013-10-24 Codexis, Inc. Production of fatty alcohols from engineered microorganisms
EP3360958B1 (en) * 2013-03-15 2021-12-22 Labrador Diagnostics LLC Thermostable blunt-end ligase and methods of use
HUE053049T2 (en) 2013-09-27 2021-06-28 Codexis Inc Automated screening of enzyme variants
GB201612011D0 (en) * 2016-07-11 2016-08-24 Glaxosmithkline Ip Dev Ltd Novel processes for the production of oligonucleotides
US10837009B1 (en) * 2017-12-22 2020-11-17 New England Biolabs, Inc. DNA ligase variants

Also Published As

Publication number Publication date
WO2018208665A1 (en) 2018-11-15
EP3635101A4 (en) 2020-09-30
AU2018266606A1 (en) 2019-11-14
PL3635101T3 (en) 2021-12-13
JP7401902B2 (en) 2023-12-20
JP2023166579A (en) 2023-11-21
CA3062550A1 (en) 2018-11-15
DK3635101T3 (en) 2021-09-20
ES2887078T3 (en) 2021-12-21
EP3635101A1 (en) 2020-04-15
HUE055411T2 (en) 2021-11-29
BR112019023337A2 (en) 2020-06-16
JP2020518278A (en) 2020-06-25
MX2019013289A (en) 2020-01-15
EP3635101B1 (en) 2021-08-18
EP3957723A2 (en) 2022-02-23
EP3957723A3 (en) 2022-04-20
KR20200003903A (en) 2020-01-10
CN110914415A (en) 2020-03-24
US20180320162A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
SG11201909957TA (en) Engineered ligase variants
SG11201909868YA (en) Compositions and methods of treating huntington's disease
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909777YA (en) Modulatory polynucleotides
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201909870SA (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG11201908539VA (en) Auto-injector
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201901006RA (en) Systems and methods for enhanced organizational transparency using a credit chain
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201901364VA (en) Engineered target specific nucleases
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201806639VA (en) New streptococcal proteases
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201803975SA (en) Improved tnf binders
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201408665XA (en) Two stage gasification with dual quench